e-learning
resources
Milan 2017
Sunday, 10.09.2017
The spectrum of CTDs: from pathogenesis to treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Rituximab in the management of idiopathic inflammatory myopathies complicated by interstitial lung disease
P. Riddell (Dublin, Ireland)
Source:
International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Session:
The spectrum of CTDs: from pathogenesis to treatment
Session type:
Thematic Poster
Number:
898
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Riddell (Dublin, Ireland). Rituximab in the management of idiopathic inflammatory myopathies complicated by interstitial lung disease. 898
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders?
Source: Eur Respir J 2011; 38: 384-391
Year: 2011
Idiopathic inflammatory myopathies and the lung
Source: Eur Respir Rev 2015; 24: 216-238
Year: 2015
Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases
Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019
Year: 2019
Rituximab therapy for interstitial lung disease in patients with antisynthetase syndrome
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Clinical features of usual interstitial pneumonia-correlation between idiopathic pulmonary fibrosis and connective tissue disease associated with usual interstitial pneumonia
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Difference of the clinical characteristics and outcome between interstitial lung disease with dermatomyositis and idiopathic interstitial pneumonia
Source: International Congress 2017 – Lung function testing
Year: 2017
Interstitial lung diseases in childhood
Source: ISSN=1025-448x, ISBN=1-904097-22-7, page=213
Year: 2002
Interstitial lung disease with autoimmune features
Source: Eur Respir Mon 2011; 54: 104-117
Year: 2011
Immunogenetic background of children´s idiopathic interstitial pneumonias and adult idiopathic pulmonary fibrosis
Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease
Year: 2010
Genomic comparison of fibrotic rheumatoid arthritis-associated ILD and idiopathic pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Cytomegalovirus antigenemina in idiopathic interstitial pneumonias and collagen vascular disease-related lung diseases treated with immunosuppressive drugs
Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Year: 2008
Longitudinal clinico-physiological behaviour of interstitial lung disease in the idiopathic inflammatory muscle syndromes
Source: Annual Congress 2010 - Different patterns of interstitial lung disease
Year: 2010
Clinical management of the idiopathic interstitial pneumonias: an example of an integrated approach to interstitial lung diseases
Source: Annual Congress 2006 - PG8 - Interstitial lung diseases: idiopathic interstitial pneumonias
Year: 2006
Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
Source: Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019
Year: 2019
Negative outcome of prednisone in possible idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF clinical
Year: 2016
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: 693-703
Year: 2005
The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype
Source: Eur Respir Rev, 27 (150) 180077; 10.1183/16000617.0077-2018
Year: 2018
Novel markers of connective tissue disease in patients with idiopathic interstitial pneumonia
Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Year: 2008
Evaluation of interstitial inflammatory cell in idiopathic interstitial pneumonias
Source: Eur Respir J 2006; 28: Suppl. 50, 99s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept